Un-audited

Audited

Sr.
No.

Particulars

Quarter ended

Quarter ended

9 Months
Ended

9 Months
Ended

Year Ended

1.

Net Sales

1,74,96

1,51,83

5,72,30

4,94,98

6,03,36

2.

Other Income

55

24

2,09

1,77

2,22

3.

Total Income

1,75,51

1,52,07

5,74,39

4,96,75

6,05,58

4.

Total Expenditure

(a)

Increase/ Decrease in Stock in Trade

14,73

-14,28

39,26

-1,78

-23,11

(b)

Consumption of Materials

50,70

63,91

2,01,77

2,03,25

2,40,79

(c)

Excise Duty

10,00

8,27

29,26

21,56

33,13

(d)

Staff Cost

49,42

40,38

1,39,28

1,16,41

1,50,94

(e)

Other Expenditure

37,00

40,49

1,24,23

1,20,59

1,54,60

5.

Profit before Interest,
Depreciation and Taxation

13,66

13,30

40,59

36,72

49,23

6.

Interest

5,26

4,46

13,24

11,66

15,61

7.

Depreciation

6,44

6,43

19,33

19,28

25,77

8.

Profit Before Tax

1,96

2,41

8,02

5,78

7,85

9.

Provision for  Current Tax

-

-

-

-

1,34

10.

Provision for Deferred Tax

-

-

-

-

(78)

11.

Fringe Benefit Tax

-

-

-

-

-

12.

Net Profit after Tax

1,96

2,41

8,02

5,78

7,29

13.

Paid up Equity Share Capital
[Net of allotment money in arrears]

3,54,35

3,54,35

3,54,35

3,54,35

3,54,35

14.

Reserves Excluding Revaluation Reserves  Less Deferred Tax  Provision.

-

-

-

-

65,26

15.

E. P. S.

-

-

-

-

0.16

16.

Aggregate of non promoter share -holding.
No. of shares
Percentages of shareholding

 30,80,150

67.38%

29,02,900

63.51%

30,80,150

67.38%

29,02,900

63.51%

29,02,900

63.51%

17.

Promoters and promoter group
Shareholding
a) Pledged/Encumbered
- Number of shares

-

-

-

-

-

- Percentage of shares (as a % of
the total shareholding of promoter and promoter group)

-

-

-

-

-

- Percentage of shares (as a% of
the total share capital of the
company)

-

-

-

-

-

b) Non-encumbered
- Number of Shares

 14,90,850

16,68,100

14,90,850

16,68,100

 16,68,100

- Percentage of shares (as a% of
the total shareholding of promoter and promoter group)

 100%

100%

 100%

100%

 100%

- Percentage of shares (as a % of
the total share capital of the
company)

 32.62%

36.49%

 32.62%

36.49%

 36.49%

STATEMENT OF ASSETS AND LIABILITES

As on 31.12.2011
(Reviewed)

As on 31.12.2010
( Reviewed)

CAPITAL & LIABILITIES

Capital
Reserve and Surplus
Secured Loan
Other Liabilities

3,54,35
2,98,50
94,59
1,53,83

3,54,35
2,82,57
1,03,84
1,60,48

ASSETS

Investment
Fixed Assets
Net Current Assets

31,59
4,31,95
4,37,73

30,10
4,47,80
4,23,34

NOTES :-

1. The above results subjected to ‘Limited Review’ by the Auditors of the Company, were taken on record by the Board of Directors of the Company, at their meeting held on   
   31-01-2012
2. The Un-audited results for the quarter do not reflect the trend for the year.
3. Income Tax provision, whatever found necessary, will be considered at the end of the year
4. The company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable
5. The Company did not have any investors’ complaint pending at the beginning of the quarter. No investors’ complaints were received during the quarter and hence no investors’ complaints remained unsolved at the end of the quarter ended 31-12-2011.